netFormulary Portsmouth and South East Hampshire NHS
Prescribing Formulary  
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
01.05.03  Expand sub section  Drugs affecting the immune response
Cytotoxic Drug Azathioprine tablets
(Gastroenterology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber with Shared Care
 
Link  Shared Care Guideline Immune modulating therapies June 2019
   
Cytotoxic Drug Azathioprine tablets
(Autoimmune Hepatitis)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber with Shared Care
 
Link  Shared care guidelines Immune modulating therapies June 2019
   
Cytotoxic Drug Mercaptopurine tablets
(Gastroenterology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber with Shared Care

Crohn's disease - unlicensed indication

 
Link  Shared care guidelines Immune modulating therapies June 2019
   
Cytotoxic Drug Methotrexate
(tablets, injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber with Shared Care

Crohn's dsease - unlicensed indication


Tablets 2.5mg


Nordimet   - prefilled pen


Metoject PEN - prefilled pen

 
Link  Shared Care guideline Immune modulating therapies June 2019
   
Vedolizumab (Entyvio®)
(injection )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine

Moderately to severely active ulcerative colitis NICE TA 342, moderately to severely active Crohns disease NICE TA 352

 
Link  NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Link  NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
   
01.05.03  Expand sub section  Cytokine inhibitors
Adalimumab (Humira® Imraldi® Amgevita®)
(injection )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Prescribe by brand name

Crohns Disease in line with NICE TA 187, moderately to severely active ulcerative colitis NICE TA 329

 
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Link  NICE TA187: Crohn’s disease - infliximab and adalimumab
   
Golimumab (Simponi®)
(injection )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
   
Infliximab (Remicade®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Severe active Crohns disease in line with NICE TA 187, Acute exacerbation of sever active ulcerative colitis NICE TA 163, Moderately to severelty active ulcerative colitis NICE TA 329.  Prescribe by brand name

 
Link  NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Link  NICE TA187: Crohns disease - infliximab & adalimumab
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
   
Infliximab (biosimilar) (Inflectra®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Severe active Crohns disease in line with NICE TA 187, Acute exacerbation of sever active ulcerative colitis NICE TA 163, Moderately to severelty active ulcerative colitis NICE TA 329.  Prescribe by brand name

 
Link  NICE TA 187 Infliximab and adalimumab for the treatment of Crohn’s disease
Link  NICE TA 329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis
Link  NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
   
Infliximab (biosimilar) (Remsima®)
(for infusion)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine

Prescribe by brand name

 
Link  NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Link  NICE TA187: Crohns disease - infliximab & adalimumab
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
   
Ustekinumab (Stelara®)
(infusion, injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 456 Ustekinumab for moderately to severely active Crohn’s disease
   
01.05.03  Expand sub section  Vedolizumab
 ....
 Non Formulary Items
Ciclosporin
(Gastroenterology)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Primary and Secondary Care (unrestricted) – may be prescribed by GPs, hospital doctors or other qualified prescribers in primary and secondary care  

Amber Initiation

Amber Initiated: first prescription from specialist, on going supplies from primary care (or when stabilised on therapy).  

Amber Recommended

Amber recommended: first prescription may be supplied by primary care under the advice of a specialist.  

Amber with Shared Care

For initiation within a specialist service followed by ongoing prescribing in primary care according to published shared care guidance  

Red

For initiation and ongoing prescribing in secondary care only. Medicines in this category may be further restricted to use by specific hospital departments only.  

Blue

For prescribing in primary care only  

netFormulary